Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|March 15, 2021
- Pharmaceutical Technology-03-15-2021
- Volume 2021 eBook
- Issue 1
A Real-World Approach to Evaluating Cleanroom Garments
Author(s)Anne Marie Dixon-Heathman
Traditional methods of testing cleanroom garments fail to test for dynamic conditions in the cleanroom. A holistic approach considers particulate shedding and heat load during processing, as well as the impact of laundering on garment life cycle.
Advertisement
Selecting the best cleanroom garments for a specific application is crucial to maintaining the integrity of aseptic processing areas. The author has developed an evaluation process, outlined in this article, that uses "real world" conditions to determine how well cleanroom garb will prevent particulate emission and maintain comfortable temperatures for operators.
Article details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 10–15
Citation
When referring to this article, please cite it as A. Dixon-Heathman, “A Real-World Approach to Evaluating Cleanroom Garments,” Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 5 years ago
It Takes a Bio/Pharma Villageover 5 years ago
Managing the Risk of Nitrosamine Impuritiesover 5 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 5 years ago
Can FDA Reinvent Inspectionsover 5 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 5 years ago
Resources, Guidelines, and Guidance Documents Directoryover 5 years ago
Regulatory and Standard Setting Organizations DirectoryAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5